If you are on the lookout for some new additions to your portfolio, then the ASX 200 shares listed below could be worth considering.
They have both been named as favoured shares by Bell Potter for the month of April. These are the shares that the broker believes "offer attractive risk-adjusted returns over the long term."
Bell Potter also notes that when choosing its picks it considers the current macro-economic backdrop and investment environment, focusing on quality companies with proven track records, capable management, and competitive advantages.
You can read about the first two ASX 200 shares on the list here. Let's now take a look at two more of the broker's top picks:
Mineral Resources Ltd (ASX: MIN)
Bell Potter is a big fan of this mining and mining services company.
It likes Mineral Resources due to the earnings diversification it has from its focus on lithium, energy, and iron ore, as well as mining services. It explains:
In contrast to its peers, MIN completes everything from engineering, to construction, to all aspects of operations in-house. Our Buy view is underpinned by MIN's earnings diversification, strong insider ownership, clearly articulated strategies, expertise in contracting and internal growth options at Onslow as well as potential lithium expansions including into downstream. All up, MIN offers diversified exposure to steady income streams from the contracting business and market-driven commodity exposure coupled with earnings derived from both lithium and iron ore.
Bell Potter currently has a buy rating and $75.00 price target on the company's shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 share that Bell Potter is feeling very bullish about is sleep disorder treatment company ResMed.
It believes ResMed has a long runway for growth thanks to its under penetrated market, increasing demand, and a major product recall from its main rival. Bell Potter explains:
The market for OSA and chronic obstructive pulmonary disease (COPD) remains under penetrated, and we expect industry volume growth to continue in the 6-8% range for the foreseeable future. In this regard, the competitive dynamics are very much in favour of RMD due to the Philips recall and improving semiconductor availability. […] Furthermore, ResMed is well-positioned to build on its dominant share even after Philips returns to the global market, with the launch of its latest continuous positive airway pressure (CPAP) device, the Air Sense 11.
The broker currently has a buy rating and $34.00 price target on ResMed's shares.
